Dr Johnson on BL-B01D1 in Locally Advanced or Metastatic Solid Tumors
June 8th 2023
Melissa L. Johnson, MD, discusses findings from the phase 1 BL-B01D1-101 trial investigating the efficacy and safety of the EGFR- and HER3-directed antibody-drug conjugate BL-B01D1 in patients with locally advanced or metastatic solid tumors, including non–small cell lung cancer.